Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)"
EBioMedicine. 2023 Mar:89:104486.
doi: 10.1016/j.ebiom.2023.104486.
Epub 2023 Feb 18.